Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler

Annals of Allergy, Asthma and Immunology

Volumn 86, Issue 1, 2001, Pages 36-43

  Noonan, Michael ^a   Karpel, J P ^b   Bensch, G W ^c   Ramsdell, J W ^d   Webb, D R ^e   Nolop, K B ^f   Lutsky, B N ^f  

^a Allergy Associates Research Center   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c UCSD Medical Center ^*

^d UCSD MEDICAL CENTER   (United States)

^e Allergy and Asthma Research Associates   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOMETASONE FUROATE; PLACEBO; SALBUTAMOL; TETRACOSACTIDE;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRY POWDER; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHARYNGITIS; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEROID THERAPY; THRUSH;

EID: 0035133078     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62353-8     Document Type: Article

References (25)

1. A Comparison of the efficacy and safety of inhaled corticosteroids in asthma
2. Compliance in clinical trials of two nonbronchodilator, antiasthma medications
3. Measuring compliance with inhaled medication in asthma
4. Non-adherence in asthmatic patients: Is there a solution to the problem?
5. Mometasone furoate. A review of its intranasal use in allergic rhinitis
6. Once-daily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: An active- and place-bo-controlled study
7. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients
8. Lack of systemic activity with intranasal mometasone furoate
9. Dose-ranging study of a new steroid for asthma: Mometasone furoate dry powder inhaler
10. Bioavailability and metabolism of mometasone furoate (MF) following administration by dry powder inhaler (DPI) and metered dose inhaler (MDI) in healthy human volunteers
11. Comparison of hypothalamic-pituitary-adrenal (HPA) axis suppression by mometasone furoate (MF) with that by fluticasone propionate (FP)
12. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma
13. Further studies on the chronotherapy of asthma with inhaled steroids: The effect of dosage timing on drug efficacy
14. How often is medication taken as prescribed?
15. Assessment of dose uniformity with the new mometasone furoate dry powder inhaler (MF-DPI)
16. Comparison of mometasone furoate dry powder inhaler (MF-DPI) with Pulmicort Turbuhaler using a new methodology for in vitro analysis of inhaler performance
17. Comparative safety and efficacy of single or twice daily administration of inhaled beclomethasone in moderate asthma
18. Chronotherapy of asthma with inhaled steroids: The effect of dosage timing on drug efficacy
19. Clinical equivalence of once-daily vs twice-daily administration of inhaled fluticasone propionate in the treatment of mild and moderate asthma
20. Factors related to the nocturnal worsening of asthma
21. Circadian basis of the late asthmatic response
22. Timing of prednisone and alterations of airways inflammation in nocturnal asthma
23. Diurnal rhythms of pro-inflammatory cytokines: Regulation by plasma cortisol and therapeutic implications